Filing Flows › Health Care › Vyome Holdings (HIND)
Vyome Holdings (HIND) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Vyome Holdings (HIND) Q2 2026 earnings results →
Q2 2026 Revenue down 46% year over year to $27K
Vyome Holdings made $27K in Q2 2026 (-46% Y/Y). Operating margin n/m, net loss $720K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $27K in Q2 2026, down 46% year over year and down 15% from the previous quarter.
Gross margin was 43.2%, down 5.3 points from Q2 2025. Operating costs exceeded revenue by $863K, an operating margin of -3200.0%. Operating expenses grew 151% against a revenue fall of 46%. The fastest-growing cost line was Research & development (+533%). The quarter ended with a net loss of $720K, narrower than the previous quarter's $1.0M loss. Minority interests bore $34K of it: to shareholders the quarter was a loss of $686K.
Operating cash flow was −$904K. Non-cash charges added back $3K of depreciation and amortization and $11K of share-based compensation. Working capital and other items used $198K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $27K | -46% | n/m | −$720K | −$904K |
| Q1 2026 | 10-Q | May 12, 2026 | $32K | -84% | n/m | −$986K | −$1.4M |
| Q4 2025 | 10-K | Mar 18, 2026 | $37K | -40% | n/m | −$1.3M | −$1.5M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $35K | -59% | n/m | −$8.6M | −$1.8M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $1.2M | -37% | -222.4% | −$2.6M | −$4.5M |
| Q1 2025 | 10-Q | May 20, 2025 | $1.1M | -43% | -198.2% | $1.5M | −$2.1M |
| Q4 2024 | 10-K | Apr 4, 2025 | $1.8M | -9% | -94.3% | −$1.8M | −$687K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Vyome Holdings
On August 15, 2025, ReShape Lifesciences Inc. (now known as Vyome Holdings, Inc.) (the “Company”) completed the merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the “Merger Agreement”), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and Vyome Therapeutics, Inc. (“Vyome”). Pursuant to the Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the “Merger”). As a result of the Merger, the Company was renamed “Vyome Holdings, Inc.” and Vyome continued under its name as Vyome Therapeutics, Inc., in each case effective before the open of trading on August 15, 2025.
In its own words, from its 10-K, filed Mar 18, 2026.
Vyome Holdings against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -46% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| HIND Vyome Holdings | Q2 2026 | $27K | -46% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Vyome Holdings 10-Q on SEC EDGAR · CIK 1427570 · Pharmaceutical Preparations
13F: who owns HIND and who is buying
More on HIND
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results